Blog

Dr. Moore on Immunotherapy and PARP Combinations in BRCA-Mutated Ovarian Cancer – OncLive


OncLive

Dr. Moore on Immunotherapy and PARP Combinations in BRCA-Mutated Ovarian Cancer
OncLive
Kathleen N. Moore, MD, assistant professor, The Stephenson Cancer Center, The University of Oklahoma, discusses combinations of immunotherapy with PARP inhibitors for patients with BRCA-mutated ovarian cancer. There is evidence for combining PARP

and more »

2018-02-09 NEWS
About Michael Zand

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.